171 related articles for article (PubMed ID: 22642330)
1. Absence of CD4 T-cell help provides a robust CD8 T-cell response while inducing effective memory in a preclinical model of melanoma.
Muccioli M; Longstaff C; Benencia F
Immunotherapy; 2012 May; 4(5):477-81. PubMed ID: 22642330
[TBL] [Abstract][Full Text] [Related]
2. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.
Roberts DJ; Franklin NA; Kingeter LM; Yagita H; Tutt AL; Glennie MJ; Bullock TN
J Immunother; 2010 Oct; 33(8):769-79. PubMed ID: 20842060
[TBL] [Abstract][Full Text] [Related]
3. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
4. In vivo depletion of CD4+CD25+ regulatory T cells in cats.
Smithberg SR; Fogle JE; Mexas AM; Reckling SK; Lankford SM; Tompkins MB; Dean GA
J Immunol Methods; 2008 Jan; 329(1-2):81-91. PubMed ID: 17980384
[TBL] [Abstract][Full Text] [Related]
5. Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help.
Côté AL; Byrne KT; Steinberg SM; Zhang P; Turk MJ
PLoS One; 2011; 6(10):e26491. PubMed ID: 22046294
[TBL] [Abstract][Full Text] [Related]
6. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
Boudousquie C; Bossi G; Hurst JM; Rygiel KA; Jakobsen BK; Hassan NJ
Immunology; 2017 Nov; 152(3):425-438. PubMed ID: 28640942
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of melanoma growth after treatment with dendritic cells in a Tyr-SV40E murine model requires CD4+ T cells but not CD8+ T cells.
Milling SW; Sai T; Silvers WK; Mintz B
Melanoma Res; 2004 Dec; 14(6):555-62. PubMed ID: 15577330
[TBL] [Abstract][Full Text] [Related]
8. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.
Casares N; Arribillaga L; Sarobe P; Dotor J; Lopez-Diaz de Cerio A; Melero I; Prieto J; Borrás-Cuesta F; Lasarte JJ
J Immunol; 2003 Dec; 171(11):5931-9. PubMed ID: 14634104
[TBL] [Abstract][Full Text] [Related]
9. The cryo-thermal therapy eradicated melanoma in mice by eliciting CD4
He K; Liu P; Xu LX
Cell Death Dis; 2017 Mar; 8(3):e2703. PubMed ID: 28333145
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
Jackaman C; Nelson DJ
Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
[TBL] [Abstract][Full Text] [Related]
11. Cognate CD4 help is essential for the reactivation and expansion of CD8 memory T cells directed against the hematopoietic cell-specific dominant minor histocompatibility antigen, H60.
Ryu SJ; Jung KM; Yoo HS; Kim TW; Kim S; Chang J; Choi EY
Blood; 2009 Apr; 113(18):4273-80. PubMed ID: 19139082
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rα
Kim SH; Cho E; Kim YI; Han C; Choi BK; Kwon BS
Nat Commun; 2021 Sep; 12(1):5314. PubMed ID: 34493727
[TBL] [Abstract][Full Text] [Related]
13. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
Shimizu J; Yamazaki S; Sakaguchi S
J Immunol; 1999 Nov; 163(10):5211-8. PubMed ID: 10553041
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
[TBL] [Abstract][Full Text] [Related]
15. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
Church SE; Jensen SM; Antony PA; Restifo NP; Fox BA
Eur J Immunol; 2014 Jan; 44(1):69-79. PubMed ID: 24114780
[TBL] [Abstract][Full Text] [Related]
17. STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice.
Wang Z; Celis E
Cancer Immunol Immunother; 2015 Aug; 64(8):1057-66. PubMed ID: 25986168
[TBL] [Abstract][Full Text] [Related]
18. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
[TBL] [Abstract][Full Text] [Related]
19. Depletion of CD4+ T cells during immunization with nonviable Listeria monocytogenes causes enhanced CD8+ T cell-mediated protection against listeriosis.
Kursar M; Köhler A; Kaufmann SH; Mittrücker HW
J Immunol; 2004 Mar; 172(5):3167-72. PubMed ID: 14978123
[TBL] [Abstract][Full Text] [Related]
20. Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory.
Jing W; Gershan JA; Johnson BD
Blood; 2009 Apr; 113(18):4449-57. PubMed ID: 19182203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]